CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 19,435	$ 12,346
Marketable debt securities	1,720	3,047
Receivables	8,062	7,685
Inventories	1,949	4,293
Other current assets	3,111	1,983
Total current assets	34,277	29,354
Property, plant and equipment	5,740	6,252
Goodwill	20,517	22,488
Other intangible assets	56,698	63,969
Deferred income taxes	913	510
Marketable debt securities	495	767
Other non-current assets	6,896	6,604
Total Assets	125,536	129,944
Current Liabilities:
Short-term debt obligations	3,585	3,346
Accounts payable	2,441	2,445
Other current liabilities	14,438	12,513
Total Current Liabilities	20,464	18,304
Deferred income taxes	5,913	6,454
Long-term debt	41,364	43,387
Other non-current liabilities	7,565	10,101
Total Liabilities	75,306	78,246
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	44,435	43,709
Accumulated other comprehensive loss	(1,699)	(1,520)
Retained earnings	32,414	34,474
Less cost of treasury stock	(25,284)	(25,357)
Total Bristol-Myers Squibb Company Shareholders' Equity	50,158	51,598
Noncontrolling Interest	72	100
Total Equity	50,230	51,698
Total Liabilities and Equity	$ 125,536	$ 129,944